Safety and Tolerability of Delayed-Release Dimethyl Fumarate Administered with Interferon Beta or Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Delayed-release dimethyl fumarate (DMF; also known as gastroresistant DMF) is indicated for relapsing multiple sclerosis (MS). The objective of this study was to explore the safety and tolerability of DMF when administered with interferon beta (IFNβ) or glatiramer acetate (GA).

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Int J MS Care

Title: International journal of MS care

Publisher: Consortium of Multiple Sclerosis Centers

ISSN: 1537-2073

ISSN (Print): 1537-2073

Publication date (Electronic): June 3 2016

Volume: 18

Issue: 3

Affiliations

[1 ] Schapiro Center for Multiple Sclerosis, Minneapolis Clinic of Neurology, Golden Valley, MN, USA (JC); Department of Neurology, University of Colorado School of Medicine, RMMSC at Anschutz, Aurora, CO, USA (TV); Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, OH, USA (RJF); and Biogen, Cambridge, MA, USA (RZ, MN, SIS, VV).

Article

DOI: 10.7224/1537-2073.2015-020

PMC ID: 4887000

PubMed ID: 27252601

SO-VID: d6d95be3-aac9-45b1-9ed6-5763a575d9de

History

Data availability:

Comments

Comment on this article

scite_

Cited by 3

See all cited by